A targeted supplementation protocol using ursodeoxycholic acid (UDCA) to protect kidney function in patients undergoing high-risk renal surgeries.
The PESTEL analysis reveals a strong technological and social foundation based on a clear biological mechanism, but highlights significant legal and economic hurdles regarding FDA approval and reimbursement for a repurposed drug. The overall viability depends on transitioning from a theoretical biochemical benefit to a standardized, regulated clinical protocol.
Political2
Economic3
Social2
Technological3
Environmental2
Legal3
The success of a clinical prophylaxis protocol depends heavily on regulatory approval, healthcare laws, and medical standards of care. · Generated 2026-09-05 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated